Etripamil

Summary

Etripamil (CHEMBL3707312) is a phase-3 clinical-stage small molecule (ATC C08DA03); indicated across 4 conditions including ventricular tachycardia and cardiovascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C08DA03
• Indications: 4 conditions
• Clinical trials: 4
• Chemistry: 452.6 Da · C27H36N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707312
Name	Etripamil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	91824132
ATC	C08DA03
Molecular formula	C27H36N2O4
Molecular weight	452.6
InChIKey	VAZNEHLGJGSQEL-MHZLTWQESA-N

SMILES: CC(C)[C@](CCCN(C)CCC1=CC(=CC=C1)C(=O)OC)(C#N)C2=CC(=C(C=C2)OC)OC

IUPAC name: methyl 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-methylamino]ethyl]benzoate

Also known as: (-)-MSP-2017, Etripamil, Etripamilo, MSP-2017, ETRIPAMIL

Patent coverage: 12 distinct patent families (28 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ventricular tachycardia	3	MONDO:0005477	HP:0004763
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
atrial fibrillation	2	MONDO:0004981	EFO:0000275

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06716021	PHASE3	NOT_YET_RECRUITING	ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT03464019	PHASE3	TERMINATED	Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
NCT02296190	PHASE2	COMPLETED	Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
NCT04467905	PHASE2	COMPLETED	ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).